EGFR and non-small cell lung carcinoma: In conclusion, expanding access to PD1/PD-L1 inhibitors as first-line monotherapy for individuals aged 40–74 years with EGFR-wildtype PD-L1 TPS≥50% advanced NSCLC over the next 10 years to target rates of 30%–95% would result in up to four times more eligible patients receiving and benefiting from the treatment, with the most notable expansion in middle-income countries.